Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ray P. McLaughlin"'
Autor:
Eoin P. Kerin, Matthew G. Davey, Ray P. McLaughlin, Karl J. Sweeney, Michael K. Barry, Carmel M. Malone, Sami Abd Elwahab, Aoife J. Lowery, Michael J. Kerin
Publikováno v:
Breast, Vol 66, Iss , Pp 227-235 (2022)
Introduction: Traditionally, Nottingham prognostic index (NPI) informed prognosis in patients with estrogen receptor positive, human epidermal growth factor receptor-2 negative, node negative (ER+/HER2-/LN-) breast cancer. At present, OncotypeDX© Re
Externí odkaz:
https://doaj.org/article/6d36598accc84767a1ca1b4ac71d4b3f
Autor:
Matthew G. Davey, Eoin Kerin, C. O'Flaherty, Elizabeth Maher, Vinitha Richard, Peter McAnena, Ray P. McLaughlin, Karl J. Sweeney, Michael K. Barry, Carmel M. Malone, William Wyns, Osama Soliman, Nicola Miller, Maccon M. Keane, Aoife J. Lowery, Michael J. Kerin
Publikováno v:
Breast, Vol 59, Iss , Pp 67-75 (2021)
Background: Human epidermal growth factor receptor-2 (HER2) is overexpressed in 20–25% of breast cancers. Complete eradication of disease following neoadjuvant therapies and chemotherapy has been referred to as pathological complete response (pCR).
Externí odkaz:
https://doaj.org/article/05e7ab55af2d4e6eb6ce465673a023fd
Autor:
Matthew G. Davey, Eoin P. Kerin, Ray P. McLaughlin, Michael K. Barry, Carmel M. Malone, Sami Abd Elwahab, Aoife J. Lowery, Michael J. Kerin
Publikováno v:
Clinical Breast Cancer.
Autor:
Donald Courtney, Matthew G. Davey, Brian M. Moloney, Michael K. Barry, Karl Sweeney, Ray P. McLaughlin, Carmel M. Malone, Aoife J. Lowery, Michael J. Kerin
Publikováno v:
Irish journal of medical science. 191(6)
Background Breast cancer mortality has decreased due to improved screening and treatment options. Nevertheless, 25–30% of patients develop disease recurrence and die from the disease dissemination. Patients who develop metastatic disease represent
Autor:
Matthew G. Davey, Amirhossein Jalali, Éanna J. Ryan, Ray P. McLaughlin, Karl J. Sweeney, Michael K. Barry, Carmel M. Malone, Maccon M. Keane, Aoife J. Lowery, Nicola Miller, Michael J. Kerin
Publikováno v:
Journal of Personalized Medicine; Volume 12; Issue 7; Pages: 1117
Background: OncotypeDX Recurrence Score© (RS) is a commercially available 21-gene expression assay which estimates prognosis and guides chemoendocrine prescription in early-stage estrogen-receptor positive, human epidermal growth factor receptor-2-n